Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Markus Magerl

Showing results (111-120 of 152) with videos related to

Pageof 16
Sort By:
The World Allergy Organization Journal|January 4, 2013
WAO Guideline for the Management of Hereditary AngioedemaTimothy Craig, Emel Aygören-Pürsün, Konrad Bork, et al.
Arerugi = [Allergy]|December 15, 2015
[WAO Guideline for the Management of Hereditary Angioedema]Timothy Craig, Emel Aygören Pürsün, Konrad Bork, et al.
Gene|May 14, 2018
Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiencyGedeon Loules, Maria Zamanakou, Faidra Parsopoulou, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Advances in Therapy|June 10, 2026
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema ProphylaxisTimothy J Craig, Mar Guilarte, Huamin Henry Li, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
The New England Journal of Medicine|October 24, 2024
CRISPR-Based Therapy for Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Markus Magerl, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 19, 2025
Authors' responseAndrea Zanichelli, Walter A Wuillemin, Aleena Banerji, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 6, 2025
Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidenceAndrea Zanichelli, Walter A Wuillemin, Emel Aygören-Pürsün, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 16

Showing results (111-120 of 152) with videos related to

Sort By:
Pageof 16
The World Allergy Organization Journal|January 4, 2013
WAO Guideline for the Management of Hereditary AngioedemaTimothy Craig, Emel Aygören-Pürsün, Konrad Bork, et al.
Arerugi = [Allergy]|December 15, 2015
[WAO Guideline for the Management of Hereditary Angioedema]Timothy Craig, Emel Aygören Pürsün, Konrad Bork, et al.
Gene|May 14, 2018
Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiencyGedeon Loules, Maria Zamanakou, Faidra Parsopoulou, et al.
The Lancet. Haematology|May 6, 2024
Garadacimab for hereditary angioedema attack prevention: long-term efficacy, quality of life, and safety data from a phase 2, randomised, open-label extension studyTimothy J Craig, Donald S Levy, Avner Reshef, et al.
Advances in Therapy|June 10, 2026
Long-Term Integrated Safety and Efficacy of Garadacimab for Hereditary Angioedema ProphylaxisTimothy J Craig, Mar Guilarte, Huamin Henry Li, et al.
Lancet (London, England)|February 27, 2022
Prophylactic use of an anti-activated factor XII monoclonal antibody, garadacimab, for patients with C1-esterase inhibitor-deficient hereditary angioedema: a randomised, double-blind, placebo-controlled, phase 2 trialTimothy Craig, Markus Magerl, Donald S Levy, et al.
The New England Journal of Medicine|October 24, 2024
CRISPR-Based Therapy for Hereditary AngioedemaDanny M Cohn, Padmalal Gurugama, Markus Magerl, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|December 19, 2025
Authors' responseAndrea Zanichelli, Walter A Wuillemin, Aleena Banerji, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|August 6, 2025
Lanadelumab's impact on hereditary angioedema control and quality of life across disease activity subgroups: Real-world evidenceAndrea Zanichelli, Walter A Wuillemin, Emel Aygören-Pürsün, et al.
Orphanet Journal of Rare Diseases|July 29, 2021
Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension studyWilliam R Lumry, Bruce Zuraw, Marco Cicardi, et al.
Pageof 16